Q-Line BiotechNSE:QLINE -5.15%12 Gross Margin % is 42.17% as of Mar. 2025, which is at its 10-year median of 42.17. GuruFocus rates NSE:QLINE with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Q-Line Biotech ranks worse than 65.71% on this metric.
The historical rank and industry rank for Q-Line Biotech's Gross Margin % or its related term are showing as below:
NSE:QLINE'
s Gross Margin % Range Over the Past 10 Years
Min: 40.86 Med: 42.17 Max: 42.84
Current: 42.17
During the past 3 years, the highestGross Margin % of Q-Line Biotech was 42.84%. The lowest was 40.86%. And the median was 42.17%.
NSE:QLINE's Gross Margin % is ranked worse than 65.71% of 805
companies
in the Medical Devices & Instruments industry
Industry Median: 51.94
vs NSE:QLINE: 42.17
Q-Line Biotech had a gross margin of 42.17% for the quarter that ended in Mar. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Q-Line Biotech was 0.00% per year.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Q-Line Biotech had a gross margin of 42.17% for the quarter that ended in Mar. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Q-Line Biotech Gross Margin % Related Terms
Q-Line Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Gross Margin % Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Gross Margin %
42.84
40.86
42.17
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Gross Margin %
42.84
40.86
42.17
NSE:QLINE vs ABT, SYK, MDT: Gross Margin % Comparison
For the Medical Devices subindustry, Q-Line Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Q-Line Biotech (NSE:QLINE) has a Gross Margin % of 42.17% as of Mar. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Q-Line Biotech and its competitors. This is near median its historical median of 42.17. Over the past decade, Q-Line Biotech's Gross Margin % has ranged from 40.86 to 42.84. According to the industry distribution chart, Q-Line Biotech ranks #529 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 65.7%.
Is Q-Line Biotech's Gross Margin % too high?
Q-Line Biotech's current Gross Margin % of 42.17% is near median its 10-year median of 42.17. Over the past 10 years, this metric has ranged from a low of 40.86 to a high of 42.84. The Medical Devices & Instruments industry median Gross Margin % is 51.94. Q-Line Biotech's value of 42.17% is 18.8% below this industry median. Based on the distribution chart, Q-Line Biotech ranks #529 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Gross Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Q-Line Biotech ranks #529 out of 805 companies for Gross Margin %. This places Q-Line Biotech in the lower half of its industry. The industry median Gross Margin % is 51.94. Q-Line Biotech's value of 42.17% is 18.8% below this benchmark. Historically, Q-Line Biotech's own Gross Margin % has ranged from 40.86 to 42.84 over the past decade. While the company's 10-year median is 42.17 vs. the industry median of 51.94, Q-Line Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 51.94, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Q-Line Biotech's current Gross Margin % of 42.17% is 18.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Q-Line Biotech and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 51.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Q-Line Biotech's current Gross Margin % is 42.17%, which is near median its own 10-year median of 42.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Gross Margin % of 42.17%. The current Gross Margin % is 42.17%, which is near median its 10-year median of 42.17 and 18.8% below the Medical Devices & Instruments industry median of 51.94. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Gross Margin % is 42.17% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 